Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04920344
Other study ID # 032008
Secondary ID Pro2020002824NCI
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 19, 2021
Est. completion date May 8, 2025

Study information

Verified date November 2023
Source Rutgers, The State University of New Jersey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer. Giving reduced dose radiation therapy and chemotherapy after surgery may improve quality of life compared with standard of care primary chemoradiation approach without compromising survival.


Description:

PRIMARY OBJECTIVE: I. To measure swallowing function and disease specific quality of life of patients with oropharyngeal cancer treated with transoral surgery and reduced intensity adjuvant therapy. SECONDARY OBJECTIVES: I. To examine kinetics of circulating tumor deoxyribonucleic acid (DNA) in patients treated with transoral surgery. II. To estimate local control, progression free and overall survival using transoral surgery and reduced intensity adjuvant therapy. OUTLINE: Based on pathologic findings after standard of care transoral surgery, patients are assigned to 1 of 3 groups. GROUP I (LOW RISK): Patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation. GROUP II (MEDIUM RISK): Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) for 5 weeks in the absence of disease progression or unacceptable toxicity. GROUP III (HIGH RISK): Patients whose tumor has a "positive margin", which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT for 6 weeks and receive cisplatin intravenously (IV) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 3 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date May 8, 2025
Est. primary completion date May 8, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven squamous cell carcinoma of the oropharynx - Clinical stage T1-2, N0-N3, M0 by American Joint Committee on Cancer (AJCC) 8 criteria - Must have tumors deemed surgically resectable with acceptable morbidity - Estimated life expectancy of at least 12 weeks - Must give informed consent - Must have Eastern Cooperative Oncology Group (ECOG) performance status =< 3 - Must have detectable circulating HPV DNA levels - Platelets >= 100,000/ul - Absolute neutrophil count (ANC) >= 1,500/ul - Hemoglobin > 8 g/dl (use of transfusion to achieve this is acceptable) - Total bilirubin < 2 X institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 3 X institutional ULN - Serum creatinine < 2 x institutional ULN or creatinine clearance > 50 ml/min as determined by 24 hour collection or estimated by Cockcroft-Gault formula - Negative pregnancy test, if applicable Exclusion Criteria: - Patients may not have received previous therapy for their head and neck squamous cell carcinoma (SCC), including chemotherapy, radiation therapy, or surgery beyond biopsy - Second primary malignancy. Exceptions are: - Patient had a second primary malignancy but has been treated and disease free for at least 3 years - In situ carcinoma (e.g. in situ carcinoma of the cervix) - Non-melanomatous carcinoma of the skin - Patients with metastatic disease beyond the neck will be excluded - Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator - Age < 18 years - Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: CD4 count is > 499/cu mm and their viral load is < 50 copies/ml. Use of highly active antiretroviral therapy (HAART) is allowed - Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 5) - Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels - Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels - Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels - Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels - Women who are pregnant, due to the teratogenic effects of radiation therapy and chemotherapy on the unborn fetus. Women of childbearing age must agree to undergo a pregnancy test prior to therapy and to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Tumor deemed unresectable with acceptable morbidity: - Tumors > 4 cm in size (T3 or higher) - Tumors of the base of tongue < 4 cm but with deep invasion of tongue musculature placing hypoglossal nerve or both lingual arteries at risk - Significant extension into hypopharynx - Extension into soft palate beyond 1/3 of the width - Clinically extensive extranodal extension (ENE) e.g. radiologic evidence of invasion of carotid artery, gross extension into sternocleidomastoid muscle or deep neck muscles. Lymph nodes larger than 6 cm without clinical ENE will be allowed

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Oropharyngeal Neoplasms

Intervention

Procedure:
Transoral Surgery
Patients will undergo transoral surgery
Radiation:
External Beam Radiation Therapy
Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
Drug:
Cisplatin
Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
Procedure:
Incisional Tumor Biopsy
Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
Other:
Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment
Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
MD Anderson Dysphagia Index
MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
University of Washington Quality of Life Questionnaire
University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
Euro-QOL 5 dimension scale questionnaire
A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Diagnostic Test:
Modified barium swallow (MBS) evaluation with aspiration-penetration scale
The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms. The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.

Locations

Country Name City State
United States Rutgers Cancer Institute of New Jersey New Brunswick New Jersey
United States RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick New Brunswick New Jersey
United States Rutgers Cancer Institute of New Jersey at University Hospital Newark New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Rutgers, The State University of New Jersey National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary MD Anderson Dysphagia Index (MDADI) MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients and has been widely used and validated in this population. The total score ranges from 20 to 100 with the higher score indicating higher level of function. At baseline.
Primary MD Anderson Dysphagia Index (MDADI) MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients and has been widely used and validated in this population. The total score ranges from 20 to 100 with the higher score indicating higher level of function. At 24 weeks post completion of therapy.
Primary MD Anderson Dysphagia Index (MDADI) MDADI is a 20 item quality of life instrument specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients and has been widely used and validated in this population. The total score ranges from 20 to 100 with the higher score indicating higher level of function. At 1 year post completion of therapy.
Secondary Locoregional control. Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model). At 3 years post completion of therapy
Secondary Disease free survival. Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model). At 3 years post completion of therapy
Secondary Progression free survival. Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model). At 3 years post completion of therapy
Secondary Overall survival. Will be assessed using survival analysis (e.g., Kaplan-Meier method and Cox proportional hazards model). At 3 years post completion of therapy
Secondary University of Washington Quality of Life Questionnaire University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients. Scoring is scaled to so that a score of 0 represents the worst possible response, and a score of 100 represents the best possible response. The higher the score - the better the outcome. At baseline, 24 weeks and 1 year post completion of therapy
Secondary European Quality of Life Five Dimension Five Level Scale Questionnaire scores Euro-QOL 5 dimension scale is a generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Euro-QOL 5 dimension scale is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers can be converted into EQ-5D index an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
At baseline, 24 weeks, and 1 year post completion of therapy
Secondary Rate of gastrostomy tube dependence Percentage of patients requiring a gastrostomy tube after completion of therapy will be analyzed using generalized linear model (GLM) analysis. At baseline, 24 weeks, and 1 year post completion of therapy
Secondary Penetration-Aspiration Score on Modified Barium Swallow examination Objective swallowing function assessment using modified barium swallow (MBS) evaluation with aspiration-penetration scale.
The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration. The higher the score, the worse is the outcome.
Baseline and 1 year post completion of therapy
Secondary Correlation of circulating tumor deoxyribonucleic acid (ctDNA) levels with known adverse pathological features Correlation of ctDNA levels at baseline with known adverse pathological features such as, number of involved lymph nodes, extranodal extension and positive margins. Will be analyzed using GLM analysis. At baseline and at 4 weeks post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05172245 - Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Phase 1
Withdrawn NCT04140513 - Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer N/A
Completed NCT04489212 - Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries N/A
Terminated NCT03618134 - Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Phase 1/Phase 2
Suspended NCT04162873 - Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Phase 2
Recruiting NCT06356272 - Oropharynx (OPX) Biomarker Trial
Recruiting NCT05232851 - A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Phase 1/Phase 2
Active, not recruiting NCT04576091 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Phase 1
Recruiting NCT04900623 - Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study Phase 2
Terminated NCT04106362 - Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma Phase 2
Recruiting NCT05541016 - Blood-Based Biomarkers to Inform Treatment and Radiation Therapy Decisions for HPV Associated Oropharyngeal Squamous Cell Head and Neck Cancers Phase 2
Recruiting NCT05136196 - BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Phase 2
Recruiting NCT03010150 - Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Recruiting NCT04533750 - Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Phase 1
Recruiting NCT03811015 - Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer Phase 3
Active, not recruiting NCT03258554 - Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Phase 2/Phase 3